投融资数据库
免费查数据
注册送3天会员
首页>投融资
Eisai
收并购
Eisai Co Ltd produces prescription drugs. The Company produces and sells diagnostic drugs. The Company also manufactures and sells foods, livestock feeds, chemicals, and agrochemicals.In December 2022, Catalyst Pharmaceuticals Inc entered into a definitive agreement with Eisai Co Ltd under which Catalyst will acquire the U.S. rights to FYCOMPA.In October 2020, Eisai Co Ltd and JD Health announced to acquire a joint venture company, Jingyi Weixiang (Shanghai) Health Industry Development Limited Company, to build a Health Service Platform for the elderly in China.In May 2019, the company had commenced a venture investment business for the purpose of excavating innovative technologies, supporting venture businesses with such technologies, and partnering with the businesses in the future, so as to accelerate innovation in drug creation as well as the establishment of ecosystem platform.In December 2015, Eisai Co entered into a business acquisition agreement with Alfresa Holdings
基本信息
-
公司全称Eisai Co Ltd
-
类型医药产品研发、生产商
-
产业领域医药研发/制造、化学&生物药
-
公司人数500人以上
-
地址Eisai Main Bldg. 4-6-10, Koishikawa BUNKYO-KU TOKYO-TO 112-8088; JP; Telephone: +81338173700;
-
联系电话03-3817-3700
-
邮箱
-
成立时间1941-12-06
相关投融资企业
A轮
Engitix LIMITED is a biopharmaceutical company that focuses on the development of therapeutics.In January 2022, Engitix Ltd announced the close of its $54m Series A financing as well as a strategic collaboration with Dompé farmaceutici S.P.A
收并购
Agenus Inc.是一家致力于开发和商业化治疗癌症和传染病疗法的生物技术公司，且主要是基于免疫学疗法。公司的技术组合由 Saponin Platform和Heat Shock Protein Platform组成。在其皂素平台包括QS-21 Stimulon佐剂或QS-21 Stimulon，正处于试验阶段，可用于治疗癌症、带状疱疹、疟疾、阿尔茨海默病、人类免疫缺陷病毒和结核。在HSP平台中正在开发重组系列及前噬菌体系列疫苗。重组系列平台的HerpV疫苗包含了QS-21 Stimulon，可用于治疗生殖器疱疹，已完成了第一阶段试验，正在进行第二阶段试验。在前噬菌体系列中，候选产品已经完成了第3期的临床试验，可用于治疗肾细胞癌。前噬菌体系列中R-100疫苗已在俄罗斯注册，用于治疗患有肾细胞癌的中期患者。此外,前噬菌体系列的g - 100和g - 200疫苗的第二阶段试验已被美国计入测试，可用于治疗神经胶质瘤的反复发作。公司的业务活动包括产品研发、知识产权诉讼、制造、管理和临床事务、企业融资和发展活动、市场开发和支持性合作。公司的候选产品需要临床试验，并经过监管机构的批准,以及市场的接受。公司部分战略是主要通过与学者、企业合作伙伴和授权人共同合作，将候选产品开发并商业化。
该公司最初作为一家特拉华州有限责任公司成立于1994年。
收并购
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases based on repeatome.In September 2021, ROME Therapeutics completed a $77 million Series B financing led by Section 32.By April 2020, the company had raised $50 million in Series A funding
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息